rss
Evid Based Nurs 12:45 doi:10.1136/ebn.12.2.45
  • Treatment

Review: weight-reducing agents improve glycaemic control and reduce progression to diabetes

S Czernichow

Dr S Czernichow, Unite de Recherche en Nutrition Humaine, Bobigny, France; s.czernichow{at}uren.smbh.univ-paris13.fr

QUESTION

How do weight-reducing agents affect glycaemic parameters and risk of type 2 diabetes in predisposed individuals?

REVIEW SCOPE

Included studies were randomised, double-blind, placebo controlled trials (RCTs) that evaluated the effects of weight-reducing agents (eg, orlistat, sibutramine, and rimonabant) on fasting glucose or glycated haemoglobin (HbA1c) concentrations and had a duration of ⩾1 year. Studies of mixed populations were excluded. Outcomes included weight loss, fasting glucose and HbA1c concentrations, and diabetes.

REVIEW METHODS

Medline was searched from November 1987 to May 2007. 23 RCTs met the selection criteria: 8 (n = 2848, mean age 55 y) assessed people with diabetes, and 15 (n = 11 821, mean age 44 y) assessed people without diabetes. All RCTs evaluated drug therapy (orlistat, 120 mg/d; sibutramine, 10–20 mg/d; or rimonabant, 20 mg/d) plus reduced-calorie diets. Meta-analysis was not done because of heterogeneity of studies.

MAIN RESULTS

Weight loss results are in the table. Weight-reducing agents improved fasting glucose and reduced incidence of diabetes in people without diabetes and decreased HbA1c in those with diabetes (table).

Weight-reducing agents v placebo in people with and without diabetes

CONCLUSION

Weight-reducing agents improve glycaemic control and reduce progression to type 2 diabetes in predisposed individuals.

ABSTRACTED FROM

Lloret-Linares C, Greenfield JR, Czernichow S. Effect of weight-reducing agents on glycaemic parameters and progression to type 2 diabetes: a review. Diabet Med 2008;25:1142–50.

Clinical impact ratings: Endocrinology 5/7; Family/general practice 6/7; General/internal medicine 6/7; Obesity 6/7

Footnotes

  • Source of funding: no external funding.

Commentary

Use of weight-reducing agents in patients with prediabetes for prevention of progression to type 2 diabetes and for improvement of glycaemic parameters in patients with type 2 diabetes is increasing. The review by Lloret-Linares et al is important because of the global obesity epidemic1 and subsequent increase in development of type 2 diabetes.2 3 Modest weight loss with lifestyle modification can prevent development of type 2 diabetes.4

The primary strength of the review by Lloret-Linares et al is the inclusion of large placebo controlled trials comparing orlistat, sibutramine, and rimonabant for preventing and managing diabetes; similar outcomes were measured across studies. The judicious addition of weight-reducing agents by healthcare providers in overall care plans for overweight patients with prediabetes or diabetes may improve outcomes. Improvement in fasting glucose concentrations and prevention of progression to diabetes in patients with prediabetes, and improvement in glycaemic control in patients with diabetes has the potential to decrease both microvascular and macrovascular complications, thereby, decreasing morbidity, mortality, and healthcare costs.3 Management of overweight is an important part of prevention and management of diabetes. Large trials, translation of research into clinical practice, and development of standards of care that include evidence-based lifestyle modification and weight-reducing agents are urgently needed.

References

Free Sample

This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of EBN.
View free sample issue >>

EBN Journal Chat

The EBN Journal Chat offers readers the opportunity to participate in discussion about research articles and commentaries from Evidence Based Nursing (EBN).

How to participate >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.